MarkWide Research - Global Market Intelligence Platform
Report Details
Historical Year
2020-2024
Base Year
2025
Forecast Period
2026-2036
Published Date
May 2026
No. of Pages
211 Pages
Delivery Format
PDF + Excel
Home›Industries›Healthcare›Pharmaceuticals›Global Adult Vaccines Market

Global Adult Vaccines Market Size, Share, and Industry Trends Forecast 2026-2036

The Global Adult Vaccines Market, assessed at $36.8 Billion in 2026, is forecast to scale to $76.05 Billion by 2035, registering a compound annual growth rate of 8.40%. Growth is propelled by expanding public health and corporate preventive care programs targeting the health of aging populations. The accelerated development and regulatory approval of mRNA vaccine platforms enables faster responses to emerging pathogens. Demand concentration is notable in countries with robust national immunization programs, including the United Kingdom, Germany, and Australia.

Global Adult Vaccines Market Intelligence

Expanded manufacturing capacity in India is reconfiguring the supply landscape for essential immunizations, particularly for low- and middle-income countries. GlaxoSmithKline plc leverages its extensive portfolio in influenza and shingles vaccines to sustain a strong market position. Sanofi specializes in a broad range of vaccines, including those for travel immunization and endemic diseases. Meanwhile, Moderna, Inc. competes on the strength of its innovative mRNA technology platform.

Adult vaccines are immunobiological agents designed to induce protective immunity against specific infectious diseases in post-adolescent populations. These formulations, which include inactivated pathogens, toxoids, and recombinant protein subunits, prevent disease by stimulating the body's adaptive immune system. Influenza vaccines constitute a mature, high-volume seasonal market segment, while newer pneumococcal and shingles vaccines offer higher margin opportunities. Preventive care applications drive most volume, with travel immunization representing a specialized, high-value niche.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce rigorous standards for vaccine efficacy, safety, and manufacturing. Recommendations from the World Health Organization (WHO) guide national immunization policies and procurement strategies in many countries. Stakeholders must navigate evolving recommendations for booster schedules and the integration of new vaccine technologies into public health frameworks.

Global Adult Vaccines Market Size and Forecast

Market Dynamics

The central dynamic shaping the adult vaccines market is the maturation of mRNA platform technology, which enables accelerated development timelines and faster responses to emerging pathogens. This technological shift alters the competitive landscape and public health response capabilities.

Growth Catalysts

  • National Immunization Programs:Expanding public health initiatives in countries like the United Kingdom and Australia are increasing uptake of vaccines for shingles and pneumococcal disease among older adults, creating consistent, state-funded demand.
  • Aging Demographics:The growing elderly population in developed economies, including Germany and Japan, directly increases the addressable market for vaccines targeting age-related vulnerabilities, such as seasonal influenza and shingles.
  • Corporate Wellness Initiatives:An increase in employer-sponsored preventive care, particularly in the United States, drives seasonal demand for influenza vaccines through on-site clinics, improving access and vaccination rates among working adults.

Market Restraints

  • Vaccine Hesitancy:Persistent public skepticism and organized misinformation campaigns create significant demand-side friction, slowing the uptake of routine and new vaccines despite regulatory approval and public health recommendations.
  • Cold Chain Complexity:Stringent, ultra-cold temperature requirements for mRNA vaccines create substantial logistical costs and infrastructure challenges, limiting equitable access in regions with less-developed supply chains.
  • Antigenic Drift:The rapid mutation of pathogens like the influenza virus necessitates annual vaccine reformulation and revaccination, which complicates manufacturing forecasts and prevents the development of long-lasting immunity.

Strategic Opportunities

  • Combination Vaccines:Developing single-injection formulations that protect against multiple pathogens, such as influenza and COVID-19, offers a pathway to improve patient compliance, reduce healthcare visits, and simplify administration logistics.
  • Therapeutic Applications:Expanding vaccine technology beyond prophylaxis into therapeutic areas, including oncology and chronic infectious diseases, represents a significant opportunity to address unmet medical needs and create new high-value markets.
  • LMIC Market Development:Leveraging expanded manufacturing capacity in India and procurement support from organizations like Gavi can increase access to newer vaccines, such as pneumococcal and HPV, in low- and middle-income countries.

Industry Challenges

  • Divergent Booster Recommendations:Conflicting guidance from the WHO, FDA, and EMA on the timing and necessity of booster doses for diseases like COVID-19 creates uncertainty for manufacturers in planning production and for governments in setting policy.
  • Manufacturing Scale-Up:The high capital expenditure and long lead times required to build and validate new biologics manufacturing facilities, particularly for novel platforms, act as a barrier to rapid and flexible supply expansion.
  • Intellectual Property Disputes:Complex patent landscapes and licensing negotiations for critical platform technologies can delay the development and commercialization of next-generation vaccines, fostering legal and competitive friction.

Report Scope

MarkWide Research
AttributesDetails
Report TitleGlobal Adult Vaccines Market
Market Size in 2026$36.8 Billion
Market Size in 2035$76.05 Billion
CAGR (2026 – 2036)8.4%
Historical Year2020-2024
Base Year2025
Forecast Period2026-2036
Segmentation
Product Type: Influenza Vaccine, Pneumococcal Vaccine, Hepatitis Vaccine, Tdap Vaccine
Delivery Mode: Intramuscular, Subcutaneous, Intradermal, Oral
End User: Hospitals, Clinics, Retail Pharmacies, Public Health Organizations
Indication: Preventive Care, Travel Immunization, Occupational Health, General Immunization
Companies CoveredGlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Pfizer Inc., CSL Limited, Johnson & Johnson, AstraZeneca plc, Moderna, Inc., Serum Institute of India Pvt. Ltd., Others
Regions Covered
North America: US, Canada, Mexico
Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Indonesia, Malaysia, Kazakhstan, Taiwan, Vietnam, Thailand, Philippines, Singapore, Australia, New Zealand, Rest of Asia Pacific
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Middle East & Africa: Saudi Arabia, UAE, Qatar, South Africa, Israel, Kuwait, Oman, North Africa, West Africa, Rest of MEA

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Global Adult Vaccines Market Strategic Shifts & Innovations

Platform-based vaccine development is fundamentally altering product pipelines and competitive strategies. This approach accelerates response times to novel pathogens and enables new therapeutic modalities beyond traditional prophylaxis, reshaping the R&D landscape.

mRNA technology platforms enable rapid design and production of vaccines by encoding antigens rather than using attenuated or inactivated pathogens. Biopharmaceutical developers are adopting this for both pandemic response and for targeting complex endemic diseases like RSV. The industry's R&D focus is migrating from traditional protein-subunit or viral-vector methods toward the speed and flexibility of nucleic acid-based platforms.

Regulatory bodies like the US FDA and the EMA have established accelerated approval pathways, such as Emergency Use Authorization and Conditional Marketing Authorisation. These frameworks compress development timelines for vaccines addressing urgent public health needs. This shift most affects the infectious disease segment, forcing manufacturers to generate real-world evidence post-launch to convert temporary authorizations into full licensure.

A shift from individual, ad-hoc vaccination to population-level, program-based procurement is becoming standard. National governments and large healthcare systems are replacing individual patient or physician purchasing with large-scale tenders and long-term supply agreements. This model is most prominent in countries with strong national immunization programs like the United Kingdom and Australia, influencing supply chain strategies.

Global Adult Vaccines Market Segmentation

Global Adult Vaccines Market Segment

Market segmentation provides a structured view of the diverse applications and product formulations within the adult vaccines sector. Understanding these categories is crucial for manufacturers to tailor research and development efforts, optimize distribution channels, and align with specific public health priorities globally.

Product Type:

The after-sales service intensity for adult vaccines varies significantly across product types, reflecting diverse administration protocols and follow-up requirements.

  • Influenza Vaccine:These seasonal formulations induce immunity against circulating influenza virus strains, requiring annual updates based on WHO recommendations. Demand concentrates in developed economies like the United States and Germany due to established immunization programs and high public awareness.
  • Pneumococcal Vaccine:Targeting bacterial pneumonia and related infections, these vaccines are particularly vital for older adults and individuals with compromised immune systems. Uptake is increasing in countries like the United Kingdom and Australia, driven by national health initiatives.
  • Hepatitis Vaccine:These immunizations protect against hepatitis A and B viruses, with global public health programs increasing access.
  • Tdap Vaccine:This combination vaccine offers protection against tetanus, diphtheria, and pertussis, recommended for adults and pregnant individuals.

Influenza Vaccine holds the largest share; momentum sits with Pneumococcal Vaccine.

Delivery Mode:

Delivery mode segmentation highlights the varied application methods, influencing patient preference and administration logistics across different healthcare settings.

  • Intramuscular:The most common route, involving injection into muscle tissue for rapid absorption and systemic immune response. This method is standard for most adult vaccines administered in clinics and hospitals.
  • Oral:Administered by mouth, these formulations offer patient convenience and eliminate needle-related anxiety, potentially increasing vaccination rates for specific pathogens. Development in this area is expanding for various vaccine types.
  • Subcutaneous:Involves injection into the fatty tissue just under the skin, suitable for vaccines requiring slower absorption.
  • Intradermal:Administered into the dermal layer of the skin, this method uses a smaller needle and dose, often for specific influenza vaccines.

Intramuscular delivery remains the established standard, while oral formulations offer expanding patient convenience.

End User:

Customer type segmentation reveals distinct procurement behaviors and access points for adult vaccines, influencing distribution strategies.

  • Public Health Organizations:These governmental and non-governmental entities procure vaccines for large-scale immunization campaigns and national stockpiles, often through tenders. Countries such as Canada and Japan rely heavily on these organizations for population-level health initiatives.
  • Retail Pharmacies:Increasingly serving as accessible vaccination points, retail pharmacies offer convenience for adult immunizations, particularly for seasonal influenza shots in the United States and France. This channel expands reach beyond traditional medical settings.
  • Hospitals:Medical institutions administer a range of adult vaccines to inpatients and outpatients, particularly for travel or occupational health.
  • Clinics:Private and public clinics provide routine adult vaccinations, forming a foundational component of primary care services.

Public health organizations drive significant procurement volumes, with retail pharmacies increasingly accessible for adult vaccination programs.

Indication:

Indication maturity reflects the varying market development stages for specific vaccine applications, from established prevention to emerging therapeutic uses.

  • Preventive Care:This segment encompasses vaccines administered to healthy individuals to prevent future disease, forming the largest volume component of the market. National immunization programs in countries like Australia and Germany prioritize these applications for widespread population health.
  • Travel Immunization:Specialized vaccines for travelers protect against diseases endemic to specific regions, representing a high-value niche market. Demand is concentrated in countries with high international travel volumes, such as the United States and the United Kingdom.
  • Occupational Health:Vaccines protecting workers from specific hazards, such as hepatitis B for healthcare professionals, fall into this category.
  • General Immunization:This broad category includes routine vaccinations for adults not specifically covered by other indications, ensuring baseline protection.

Preventive care forms the largest application segment, with travel immunization offering higher value per dose.

Global Adult Vaccines Market Segmentation

Need this report tailored to your region?

Request specific countries, segments, or companies — tailored to your requirements.

Regional Outlook

The US Food and Drug Administration (FDA) and other national regulatory bodies influence adult vaccine market access and development across diverse global regions. These agencies establish stringent efficacy and safety standards, directly shaping market dynamics and product availability. This regulatory oversight ensures that vaccines meet high quality thresholds, fostering public trust and guiding procurement policies in key markets.

United States

Corporate wellness initiatives and an expanding aging demographic drive consistent demand for adult vaccines in the United States. The FDA's rigorous approval pathways ensure high product quality and safety for new vaccine introductions. Major biopharmaceutical clusters in Boston and the San Francisco Bay Area lead research and development for novel vaccine platforms.

Germany

Germany's aging population and well-established national health insurance system create a stable market for adult immunizations. The European Medicines Agency (EMA) sets comprehensive standards for vaccine authorization and post-market surveillance across the European Union. Pharmaceutical manufacturing centers in Bavaria and North Rhine-Westphalia contribute significantly to vaccine production and supply.

United Kingdom

National immunization programs and comprehensive public health campaigns in the United Kingdom increase uptake of vaccines for older adults. The National Health Service (NHS) plays a central role in vaccine procurement and distribution, ensuring widespread access. Research institutions in Oxford and Cambridge are at the forefront of vaccine innovation, particularly in mRNA technology.

Australia

Australia's strong national immunization programs and focus on preventive care applications generate steady demand for adult vaccines. The Therapeutic Goods Administration (TGA) regulates vaccine approvals and monitors their safety and effectiveness within the country. Public health initiatives in Melbourne and Sydney concentrate on expanding vaccination coverage for age-related vulnerabilities.

India

India's expanded manufacturing capacity is reconfiguring the global supply landscape for essential immunizations, particularly for low- and middle-income countries. The Central Drugs Standard Control Organization (CDSCO) oversees vaccine manufacturing and distribution within the country. Major vaccine production hubs in Pune and Hyderabad are critical for global supply chains.

Global Adult Vaccines Market Key Industry Players

Established pharmaceutical giants and innovative biotechnology firms split the market for adult vaccines, reflecting diverse strategic approaches. Large, diversified companies leverage extensive portfolios and global distribution networks for market penetration. Smaller, specialized firms focus on advanced platform technologies. Competitive activity centers on capacity expansion and strategic technology licensing.

Within the established pharmaceutical segment, GlaxoSmithKline plc and Sanofi exemplify companies with broad vaccine portfolios and significant market presence. These firms often compete on the strength of their existing product lines and global reach. Moderna, Inc. represents the innovative biotechnology archetype, competing on the strength of its novel mRNA technology platform and accelerated development timelines.

Leading Market Players
GlaxoSmithKline plc
Merck & Co., Inc.
Sanofi
Pfizer Inc.
CSL Limited
Johnson & Johnson
AstraZeneca plc
Moderna, Inc.
Serum Institute of India Pvt. Ltd.
Others
Please note: The company list above is for reference and is subject to change. The final study will cover 15–20 leading companies in this market, and the final selection can be tailored to the client’s specific requirements.

Cost & Logistics Intelligence

India's expanded manufacturing capacity for essential immunizations directly influences global pricing dynamics, particularly for low- and middle-income countries. This supply concentration shifts margin pools towards efficient, high-volume producers.

Pricing Analysis

Price differentiation for adult vaccines varies significantly across countries, reflecting differing national immunization program budgets and procurement strategies. Contract-based long-term offtake agreements dominate procurement by public health organizations, driving per-unit transactional pricing. Brand premium and regulatory approval status in major markets like the US and EU serve as key differentiation drivers. Pricing softness is evident in low- and middle-income countries due to Gavi support, while developed economies with robust public health systems show less price sensitivity.

Supply Chain Analysis

Serum Institute of India Pvt. Ltd. and other major pharmaceutical manufacturers in India hold substantial contract manufacturing capacity for adult vaccines. Geographic supply concentration centers on India and China for active pharmaceutical ingredients, with fill-and-finish operations distributed globally. Raw material dependencies include specialized bioreactor components and lipid nanoparticles for mRNA vaccines. Cold chain complexity, particularly for ultra-cold mRNA vaccines, presents a significant logistics chokepoint. Distribution runs through a dual model of direct government procurement and specialized pharmaceutical distributors.

Global Adult Vaccines Market SWOT Analysis

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Analyst Recommendations

The adult vaccines market is in an early-cycle expansion phase, driven by the maturation of mRNA platform technology. This technological shift enables accelerated development timelines for novel vaccine candidates, increasing adoption.

For Market Incumbents: Insulate core market share by diversifying vaccine portfolios beyond traditional influenza and shingles offerings. Invest in mRNA platform technology through strategic licensing or internal R&D to counter emerging biotech threats. Strengthen cold chain infrastructure in key geographies to maintain distribution advantage against new entrants. Leverage existing relationships with public health organizations to secure long-term procurement contracts.

For New Entrants and Emerging Players: Establish a beachhead in therapeutic applications or combination vaccine development, targeting unmet medical needs. Focus on developing novel oral formulations to improve patient compliance and penetrate underserved markets. Prioritize regulatory approval pathways in accelerated frameworks like FDA Emergency Use Authorization. The most penetrable segment lies in specific, high-value travel immunization niches.

For Investors and Strategic Acquirers: Capital is best deployed toward innovative biotechnology firms with proven mRNA platform capabilities or novel delivery technologies. Long-term viability hinges on companies addressing both prophylactic and therapeutic vaccine applications. Target acquisition archetypes include specialized R&D houses with strong intellectual property in nucleic acid-based vaccines. Watch for increased licensing agreements between large pharma and biotech as an inflection indicator.

Strategic InitiativeIndustry Significance
Pipeline DiversificationGlaxoSmithKline plc expands beyond influenza into RSV, broadening disease coverage.
Manufacturing Scale-UpSerum Institute of India increases capacity for pneumococcal vaccines, enhancing global supply.
Strategic PartnershipModerna, Inc. collaborates on mRNA delivery systems, accelerating technological advancements.
Regulatory Approval PathwaySanofi pursues accelerated EMA authorization for new formulations, shortening market entry.
Combination Vaccine DevelopmentPfizer Inc. invests in single-injection influenza and COVID-19 shots, improving patient compliance.

Research Approach

Desk research of regulatory filings, public health reports, and scientific literature preceded structured interviews with vaccine development executives, public health officials, and hospital procurement managers. Primary insights were validated against secondary data from WHO guidance, FDA approvals, and national immunization program statistics. This approach allowed for bottom-up market sizing and top-down validation of segment projections.

Forecasts assume stable macroeconomic conditions and consistent public health funding across the analysis window. The analytical framework modeled market segmentation by product type, delivery mode, end user, and indication. Compound annual growth rates were derived from historical data, demographic shifts, and anticipated regulatory changes. Key forecast inputs included vaccination rates and new vaccine pipeline progress.

Macroeconomic conditions sit as an overlay; deviation in global healthcare spending or public health policy changes would shift the trajectory. Forecasts reflect assumptions regarding vaccine hesitancy and supply chain stability. Quarterly review of national immunization program updates and new pathogen emergence is advised to detect inflection.

Need Custom Data?

Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.

1,000+

Global Clients

150+

Countries Covered

65,000+

Reports Available

Frequently Asked Questions

Why Work With MWR

Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.

Ready to access intelligence that moves business?

Browse Reports →

Trusted by Global Leaders

From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.

Multi-Language Support

Research available in French, German, Spanish, Chinese, and more.

ISO & IAF Certified

Globally aligned quality standards ensuring methodological discipline and data integrity.

Competitive Relevance

Free inclusion of 3–4 additional companies of your choice in every report.

Customized Insights

Tailored intelligence for market entry, niche expansion, or competitive benchmarking.

Post-Sale Assistance

Dedicated coordination to help interpret findings and address queries post-delivery.

Cutting-Edge Methods

Structured data collection, advanced analytics, and expert validation for reliable forecasts.

Value for Investment

Credible, structured intelligence at a cost that makes strategic sense.

What Our Clients Say

"

My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.

Accenture

"

We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.

Mondelez

Director of Global Consumer Insights

"

For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.

BCG

"

We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.

Siemens

Head of Industrial Digitalization

"

During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.

KPMG

Advisory Partner

"

We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.

Deloitte

Lead Consultant, Sustainability Services

"

For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.

Samsung

"

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.

3M

"

I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.

VITO

Buy Now